JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. Rao TN, Hansen N, Hilfiker J, Rai S, et al. Blood 2019;134:1832-1846.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Rao TN, Hansen N, Hilfiker J, Rai S, et al. JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. Blood 2019;134:1832-1846.
PMID: 31511238